2020 Public Disclosures

Data Request IDLead InvestigatorInstitutionResearch Proposal TitlePublic DisclosureData Contributor(s)Altmetric ScorePubMed Citation Total
3320John FrewRockefeller UniversityAnalysis of Outcome Measures in Hidradenitis SuppurativaFrew, J., Jiang, C., Singh, N., Grand, D., Navrazhina, K., Vaughan, R. and Krueger, J. (2020), Dermal Tunnels Influence Time to Clinical Response and Family History Influences Time to Loss of Clinical Response in Hidradenitis Suppurativa Patients Treated with Adalimumab.
Clinical and Experimental Dermatology. Accepted Author Manuscript.

doi: 10.1111/ced.14448		AbbVie
07
3320John FrewRockefeller UniversityAnalysis of Outcome Measures in Hidradenitis SuppurativaFrew J, Jiang C, Singh N, Navrazhina K, Vaughan R, Krueger J, Quantifying the Natural Variation in Lesion Counts Over Time in Untreated Hidradenitis Suppurativa: Implications
for Outcome Measures and Trial Design, JAAD International (2020),

doi: 10.1016/j.jdin.2020.09.005

AbbVie
5
3369Michael WardNational Institutes of Health (NIH)Predicting Treatment Response to Tumor Necrosis Factor Inhibitors in Patients with Ankylosing SpondylitisWang R, Dasgupta A, Ward M. Predicting Major Treatment Response to Tumor Necrosis Factor Inhibitors in Patients with Ankylosing Spondylitis [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10).

https://acrabstracts.org/abstract/predicting-major-treatment-response-to-tumor-necrosis-factor-inhibitorsin-patients-with-ankylosing-spondylitis/.		AbbVie, Pfizer
N/AN/A
4116Sharon StrausSt. Michael's HospitalComparative safety and effectiveness of cognitive enhancers for Alzheimer's dementia a systematic review and individual patient data network meta-analysisVeroniki AA, Ashoor H, Rios P, Seitidis G, Mavridis D, Holroyd-Leduc J, Straus S, Tricco A. Comparative safety and efficacy of cognitive enhancers for Alzheimer’s dementia: An individual patient data network meta-analysis. In: Advances in Evidence Synthesis: special issue. Cochrane Database of Systematic Reviews 2020;(9 Suppl 1):455.

doi: 10.1002/14651858.CD202001		AbbVie
50
4117John FrewRockefeller UniversityPredictors of Treatment Response, Adverse Events, Changes in Anaemia status and Assessment of Lesion Count Variability in Hidradenitis Suppurativa Malignancy and Infection Risk During Adalimumab Therapy in Hidradenitis Suppurativa. Frew, J., Jiang, C., Singh, N., Grand, D., Navrazhina, K., Vaughan, R. and Krueger, J. (2020), Clin Exp Dermatol. Accepted Author Manuscript.

doi: 10.1111/ced.14264

AbbVie
05
4319Maria Alice FranzoiJules Bordet Institut Clinical implications of body mass index and weight in metastatic breast cancer patients receiving abemaciclib. A combined individual patient level data sub-analysis of MONARCH 2 and MONARCH 3 trials153P Clinical implications of body mass index (BMI) and weight in metastatic breast cancer (BC) patients treated with abemaciclib and endocrine therapy: A pooled individual patient level data analysis of MONARCH 2 and MONARCH 3 trials. Franzoi, M.A. et al. Annals of Oncology, Volume 31, S71.

doi: 10.1016/j.annonc.2020.03.253		Lilly
N/AN/A
4319Maria Alice FranzoiJules Bordet Institut Clinical implications of body mass index in metastatic breast cancer patients treated with abemaciclib and endocrine therapyMaria Alice Franzoi, MD, Daniel Eiger, MD, Lieveke Ameye, MSc, Noam Ponde, MD, Rafael Caparica, MD, Claudia De Angelis, MD, Mariana Brandão, MD, Christine Desmedt, PhD, Serena Di Cosimo, MD, Nuria Kotecki, MD, Matteo Lambertini, MD PhD, Ahmad Awada, MD PhD, Martine Piccart, MD PhD, Evandro de Azambuja, MD PhD, Clinical implications of body mass index in metastatic breast cancer patients treated with abemaciclib and endocrine therapy, JNCI: Journal of the National Cancer Institute, djaa116,

doi: 10.1093/jnci/djaa116		Lilly
22
4327Michael SzarekSUNY Downstate Medical CenterAnalysis of Total Events and Hospitalizations in the SPARCL StudySzarek M, Amarenco P, Callahan A, DeMicco D, Fayyad R, Goldstein LB, Laskey R, Sillesen H, Welch KM; SPARCL Committees and Investigators. Atorvastatin Reduces First and Subsequent Vascular Events Across Vascular Territories: The SPARCL Trial. J Am Coll Cardiol. 2020 May 5;75(17):2110-2118. doi: 10.1016/j.jacc.2020.03.015. Epub 2020 Mar 16.

doi: 10.1016/j.jacc.2020.03.015		Pfizer
18
4540Chris GaleUniversity of LeedsEfficacy and safety of edoxaban versus warfarin in patients with atrial fibrillation and frailty insights from the ENGAGE AF-TIMI 48 trialWilkinson, C., Wu, J., Searle, S.D. et al. Clinical outcomes in patients with atrial fibrillation and frailty: insights from the ENGAGE AF-TIMI 48 trial. BMC Med 18, 401 (2020).

doi: 10.1186/s12916-020-01870-w		Daiichi Sankyo
54
5895, 6117Ashley HopkinsFlinders UniversityPredictors of exposure, therapeutic and adverse effects of atezolizumab used in the treatment of advanced cancersConcomitant Proton Pump Inhibitor Use and Survival in Urothelial Carcinoma Treated with Atezolizumab. Ashley M. Hopkins, Ganessan Kichenadasse, Christos S. Karapetis, Andrew Rowland and Michael J. Sorich.
Clin Cancer Res October 15 2020 (26) (20) 5487-5493;

doi: 10.1158/1078-0432.CCR-20-1876		Roche
49
5930Youssef ZeidanAmerican University of Beirut Medical CenterEvaluation of Radiotherapy Boost in Women with HER-2 positive Breast CancerAbi Jaoude J, Kayali M, de Azambuja E, Makki M, Tamim H, Tfayli A, El Saghir N, Geara F, Piccart M, Poortmans P, Zeidan YH. De-intensifying radiation therapy in HER-2 positive breast cancer: to boost or not to boost?. International Journal of Radiation Oncology-Biology-Physics. 2020 Nov 15;108(4):1040-6.

doi : 10.1016/j.ijrobp.2020.06.078		Roche
2
5933, 5208Ahmad AbuhelwaUniversity of South Australia Predictors of exposure, therapeutic and adverse effects of certolizumab pegol, baricitinib and tocilizumab used in the treatment of rheumatoid arthritisAbuhelwa, A.Y., Hopkins, A.M., Sorich, M.J. et al. Association between obesity and remission in rheumatoid arthritis patients treated with disease-modifying anti-rheumatic drugs. Sci Rep 10, 18634 (2020).

doi: 10.1038/s41598-020-75673-7		Roche
18